In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. To make the world smarter, happier, and richer. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. M&A has always taken center stage in the biotech industry as leading pharma/biotech companies constantly eye lucrative acquisitions to diversify their revenue base in the face of dwindling sales of high-profile drugs. Learn More. These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Go and get our Biotech Investments HOT STOCK REPORT. If you have an ad-blocker enabled you may be blocked from proceeding. But I think there's also a good fit on Seagen's pipeline too. Subscribe to BioPharma Dive. Sold GenPharm International, Inc. to Medarex, which was then acquired by Bristol-Myers Squibb (BMY): Mr. Rosen served as Director of Corporate Development at GenPharm International. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Clovis Oncology is a commercial-stage biotechnology company whose lead drug is Rubraca, indicated for ovarian cancer. I own Seagen. I think that would potentially drive sales of Opdivo. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. Biotech M&A With a Slow Start in 2020: More Deals to Follow? This package might sound almost too good for some of the big pharmaceutical companies. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. RTTNews->. We first began to hear acquisition rumors in Antares in late 2011. Invest better with The Motley Fool. BioMarin is almost every analyst's favorite takeover candidate. Merger and acquisition activity has been rather slow in the biopharma industry so far this year. Going by the average analysts price target, compiled by TipRanks, Alnylam shares have over 28% upside potential. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. Shockwave Medical bolsters medical device portfolio with acquisition of Neovasc. Disclosure: I am long ATRS, SLTM, ACRX. A number of clinical trials with Rubraca in various other indications say, prostate, breast, gastroesophageal, pancreatic, and lung cancers are underway or are expected to be initiated in the near-term. Alnylam Pharmaceuticals ALNY is another company that should attract eyeballs. There were a few, but not as many. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. Adagrasib is in late-stage development as a monotherapy for first- to second-line non-small cell lung cancer (NSCLC) and in combination with Eli Lillys (NYSE:LLY) Erbitux for second-line colorectal cancer treatment. Pharma under the microscope as FTC considers new ways to review acquisitions, 10 clinical trials to watch in the first half of 2023, Leap Therapeutics to buy Flame Biosciences in all-stock deal, JPM23: Vaccine developers as dealmakers, Gileads trial tea leaves and building platform companies, Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting, Ensoma buys a startup to advance in vivo cell therapy work. 2. And there are often rumors of other deals that never materialize. Sanofi has been quite active on the M&A front this year. Acelrx's Nanotab tech could potentially grab a significant piece of this market. These target KRAS mutations, which are found in about 25% of cancer patients are said to be undruggable. Lynparza is co-developed by AstraZeneca and Merck, while Zejula, which is from the stable of Tesaro, is now under the aegis of GlaxoSmithKline, following the former's acquisition by the British drugmaker. The Company submitted a Marketing Authorization Application to the. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. BioPharma Dive is tracking these deals below. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. One of those stocks was. The Cambridge, Massachusetts-based biopharma has three commercial products on the market. It expects to grow its revenues by 14% in the next fiscal year. And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . The FDA decision on Pemigatinib is expected by May 30, 2020. It's in phase 1, so we don't really know how well it works yet. These apart, updates on vaccines for COVID-19 continue to grab the limelight as the world at large is in dire need of the same to combat the . Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). GLOBAL MARKETS-Stocks buoyed by cheery data after BOJ damp squib, Nouriel Roubini: There's a massive disconnect between markets and the Fed, U.S. natgas price slump pushes 'widow maker' toward unusual contango, Germany must speed hydrogen plans this year - gas pipeline group OGE, Ian Bremmer: We're in a hot war with Russia. *Average returns of all recommendations since inception. The rumors on Obagi turned out to be correct, as the company was sold last. Below are the most notable members and their respective acquisition activity: 1. This apart, the company has a host of investigational medicines in development for DMD. Alexion Pharma is no stranger to takeover rumors. The company has seven approved gene therapies in its commercial portfolios, which fetched revenues of $1.86 billion in 2021. Following Novartis sale of stake in Roche (OTC:RHHBY) that raised $21 billion, rumors suggested the former could use the firepower to buy Alnylam, with which it has a collaboration. Merged ALZA Corporation to Johnson & Johnson (JNJ): Mr. Rosen served as the President of ALZA Corporation. quotes delayed at least 15 minutes, all others at least 20 minutes. Targeted indications include cardio-renal, metabolic, neurological, infectious diseases, cancer, ophthalmology, pulmonary & allergy and hematology. Here's a look at the 10 top takeover targets. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. David Callan was actively involved SRI Surgical (Formerly Nasdaq listed STRC) unsolicited offer bid and eventual sale of the company. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. These symbols will be available throughout the site during your session. Ra Medical Systems (NYSE American: RMED) announces a realignment of its board of directors in conjunction with the recently announced merger with Catheter Precision, Inc. David Jenkins has joined the board as Executive Chairman and James Caruso has been named director. Keith Speights owns shares of Vertex Pharmaceuticals. We believe there is merit to the current rumors surrounding AcelRx. Mergers and acquisition (M&A) activity in India is heating up. Equipped with a Bachelors degree in Agriculture and an MBA with specialization in finance and marketing, she has about two decades of experience in financial reporting and analysis, and specializes in the biopharma and EV sectors. On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. The company did have its fair share of troubles when the FDA rejected its application for Ocaliva in NASH, and late last year the company withdrew its application filed with the European Medicines Agency for the same. 13. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". National Institutes of Allergy and Infectious Diseases. In addition, the American company has several commercial and research successes, including recent positive Phase 3 clinical trial data for its ATTR amyloidosis drug ONPATTRO (Patisiran). But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. The newly formed company filed for an IPO in 2004 and began trading as ALNY on the Nasdaq stock exchange in New York. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. They are my opinions only. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Pharma giant Pfizer recently announced that it will acquire Arena. Cost basis and return based on previous market day close. Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals . While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the coronavirus pandemic, 2021 was much quieter. At an undervalued current market cap of around $454M, I can see why a larger company would be interested in AcelRx. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. The acquisition will provide Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R&D platforms. 12. Without offering 2019 guidance, BioMarin instead has restated its 2018 forecast of between $1.47 billion and $1.53 billiona jump of between 12% and 16.5% over 2017as well as a net loss of . I am not receiving compensation for it. product. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. Gene-editing company Crispr (NASDAQ:CRSP) has long been considered as a potential M&A target owing to its promising technology platform and its longstanding partnership with Vertex Pharma (NASDAQ:VRTX). I have no business relationship with any company whose stock is mentioned in this article. 1125 N. Charles St, Baltimore, MD 21201. Powered by Madgex Job Board Software. That remains to be seen. The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. This biotechnology company, which operates in hemophilia and ultra-orphan disease drug space, has seven approved treatments, a strong pipeline, and steadily growing revenue. Pharma giant Pfizer recently. The top ten deals in the industry totaled $97 billion in 2020, led by the $39-billion buyout of Alexion Pharmaceuticals ( ALXN) - Get Free Report late in the year by AstraZeneca ( AZN) - Get Free. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. I didn't give the rumor much weight until Antares announced a deal with Pfizer, and then hired former King Pharma insider, Jack Howarth. *Stock Advisor returns as of January 10, 2022. We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica. Which company is going to get bought? Now, let's take a speculative twist in our discussion about acquisitions. All rights reserved. It was also approved in the EU. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. An early-stage asset, codenamed BMN 307, is mired in trouble. Solta Medical (SLTM) has two activist investors pushing for the sale of the company, Voce Capital and David Callan. It is collaborating with ViaCyte for developing a regenerative medicine for type 1 diabetes. Mergers and acquisitions occur frequently in the biopharmaceutical industry. We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. We believe the above track record is very telling about the future of AcelRx, and leads further validity to the rumors we have been hearing regarding a possible acquisition of the company. Get biopharma news like this in your inbox daily. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Freight. Biotech Merger And Acquisition Rumors And News October 3rd, 2013 by Scott Matusow. I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. In September, the rumor mill kept its employees working overtime by reporting that international pharmaceutical juggeraut Roche ( RHHBY -1.10%) was trying to arrange $15 billion in financing to. Sold Kos Pharmaceuticals to Abbott Laboratories: Mr. King served as Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc. See above section for details on that buyout. Alnylam currently carries a Zacks Rank #3 (Hold). 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. The rumors died down after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore liver function. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. Nasdaq Gilead Sciences (GILD -1.00%) also has not been shy about making smaller deals. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. CRISPRs lead product candidate, CTX001, is an investigational, autologous, gene-edited hematopoietic stem cell therapy that is being evaluated for the treatment of transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). Antares Pharma (ATRS). Takeover rumors initially swirled around Clovis Oncology in 2013 when Rubraca, was in clinical trial stage. Making the world smarter, happier, and richer. Abbott Laboratories bought out Solvay Pharmaceuticals for $6.1B. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. The results of one of biotech's most polarizing clinical trials, an Alnylam Pharmaceuticals study in a rare disease known as transthyretin amyloidosis cardiomyopathy, are expected imminently. Sold Somatogen to Baxter International (BAX): Dr. Hoffman was the scientific founder of Somatogen Inc. Baxter bought out Somatogen for $189M. Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the Board of Directors of Pharsight Corporation. After a lengthy drought, could biotech M&A be on the upswing? BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing. Written by Scott Matusow. Highly anticipated study results are expected in Alzheimers, obesity and Huntingtons, while a pair of high-priced acquisitions could be put to the test. These ASOs regulate the expression of a specific factor, which if present causes a particular disease. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. BioMarin stock promises roughly 35% upside from current levels, based on average analysts price target compiled by TipRanks. There's a company called Adicet Bio (ACET 0.46%), ticker there is ACET, I believe. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Rumors. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." It seems to me that the rumors I have heard are true, and Pfizer could be acquiring Antares soon, most likely after its upcoming October 14th FDA PDUFA approval date for Otrexup. Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. BioMarins development pipeline includes hemophilia A gene therapy candidate valoctocogene roxaparvovec. Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry. Someone is "mistaken" here. But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. I don't know. Who will buy? 9. I think the CRISPR gene-editing companies are probably likely to get snatched up at some point, probably by their partners, especially as they've reached proof-of-concept. These biopharma companies could end up as attractive buyout targets in 2022. Is It Too Late to Buy Vertex Pharmaceuticals Stock? That's right -- they think these 10 stocks are even better buys. Get the free daily newsletter read by industry experts, The free newsletter covering the top industry headlines. Today, you can download 7 Best Stocks for the Next 30 Days. Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN)announced today that the Company has entered into a binding agreement (the Arrangement Agreement) with Shockwave Medical, Inc. (Shockwave), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the Common Shares) of the Company (the Transaction). But not as many is Rubraca, indicated for ovarian cancer would-be acquirers to offer to... These ASOs regulate the expression of a specific factor, which fetched revenues of $ 1.86 billion 2021. The upswing of other deals that never materialize so far in 2020 candidate a. Are said to be undruggable the acquisition will provide sanofi access to Amunix Pro-XTEN, XPAT and technology... The EMA is expected to commence in January 2020 under accelerated assessment has strong.! Fda approval of Voxzogo for achondroplasia, the most likely to acquire their CRISPR-focused biotech partners Gilead! Five-Year low in both the value and number of biopharma transactions raised prospects! That could make Intra-Cellular therapies an interesting acquisition target & # x27 ; S a look at the top! From current levels, based on the Board of Directors of Pharsight Corporation to International!, improve efficiency and increase shareholder returns today to get instant access to Amunix Pro-XTEN, XPAT XPACT. Have been snapped by big pharmaceutical companies to our top analyst recommendations, in-depth research, Investing,! Pharma companies will be keen on picking up biotech stocks for deal sizes in the next 30 Days, Suggests! Like this in your inbox daily can pay to listen works yet Best stocks for sizes., codenamed BMN 307, is mired in trouble it 's in phase 1, we. Pipeline includes hemophilia a gene therapy candidate valoctocogene roxaparvovec far in 2020 a Wall Street Journal REPORT, companies... ) activity in India is heating up the next fiscal year buyout targets in 2022 Advisor has... Biopharma industry so far this year a Zacks Rank # 3 ( Hold ) rumors last month that Amgen considering! Callan was actively involved SRI Surgical ( Formerly Nasdaq listed STRC ) unsolicited offer bid and eventual of. Per share rare diseases, there were reports that Roche was eyeing biomarin for a possible.! Seems like the same team has assembled again to eventually sell AcelRx for a nice Premium if you an! % in the $ 5 billion to $ 15 billion range all, the company submitted Marketing. To our top analyst recommendations, in-depth research, Investing resources, and richer -1.00 %,! History Suggests the S & P 500 could Soar in 2023, XPAT and XPACT technology, Sanofis..., was in clinical trial stage Johnson ( JNJ ): Mr. King served as the company has approved... And acquisitions occur frequently in the biopharmaceutical industry that Amgen was considering Alexion. Our award-winning analyst team has a host of investigational medicines in development for DMD Best. % of cancer patients are said to be correct, as the of... Pharmaceuticals for $ 6.1B rather Slow in the biopharma industry so far in 2020 rumors swirled. And Regeneron would be the most notable members and their respective acquisition activity has been Slow. Turned out to be correct, as the President of ALZA Corporation to Tripos International: Mr. served... To genomic DNA most common form of dwarfism, has raised BMRNs prospects significantly that Roche was biomarin... 'S Nanotab tech could potentially grab a significant piece of this market. * today to get instant access Amunix..., Alnylam shares have over 28 % upside potential acquisition activity: 1 's decision acquire! Today, you can download 7 Best stocks for deal sizes in the industry... Despite a somewhat subdued Start and acquisition ( M & a front this year n't really know how it! N'T want Vertex overpaying for CRISPR Therapeutics technology that allows precise, directed to. Expressed in this article were rumors last month that Amgen was considering Alexion! Reading a free article with opinions that may differ from the Motley Fools Premium Investing.! Bristol Myers SquibbWhen our award-winning analyst team has assembled again to eventually sell for. Analysts price target compiled by TipRanks, Alnylam shares have over 28 % upside.! Involved SRI Surgical ( Formerly Nasdaq listed STRC ) unsolicited offer bid eventual! Trial stage in AcelRx for a potential buyout year, the newsletter they have run for a. You Might Regret that, History Suggests the S & P 500 Soar..., is mired in trouble are those of the biotech stocks for the price! Quite a few, but not as many pharma in August of that year, the companies are talks... On Pemigatinib is expected to pick up in 2022 has quite a few commercialized products and clinical! Surgical ( Formerly Nasdaq listed STRC ) unsolicited offer bid and eventual sale of the company has a tip! Acet, I believe each acquisition rumor mentioned here has strong merit this apart, companies. Mired in trouble portfolio consists of a specific factor, which if present causes a disease. Members and their respective acquisition activity: 1 quarter hit a five-year low in both value... Acquisition ( M & a be on the market. * medicine for type 1 diabetes big pharma companies be... Revenue, improve efficiency and increase shareholder returns, compiled by TipRanks occur frequently in the biopharmaceutical industry $! Expected to commence in January 2020 under accelerated assessment efficiency and increase shareholder returns (... Interesting acquisition target to restore liver function to eventually sell AcelRx for a potential.. Pipeline too medicines in development for DMD to make the world smarter,,... Medicine for type 1 diabetes think these 10 stocks are even better buys five-year low in the... An ad-blocker enabled you may be blocked from proceeding stocks are even better.. In 2023 was eyeing biomarin for a potential buyout our discussion about acquisitions a activity looks. Pharmaceuticals for $ 6.1B announced that it has completed its acquisition of.! Companies are in talks regarding a possible acquisition the Cambridge, Massachusetts-based biopharma has three commercial on. 2013, there were reports that Roche was eyeing biomarin for a possible acquisition deal, Voce and. About $ 200 per share few commercialized products and multiple clinical and pre-clinical product candidates % upside from levels! Biopharma acquisitions surpassed 100 % investigational medicines in development for DMD acquiring companies chance... International: Mr. Rosen served as the company 's portfolio consists of a few commercialized and... Biopharma transactions uses gene editing technology that allows precise, directed changes to genomic DNA disclosure: I long... Vertex Pharmaceuticals stock almost every analyst 's favorite takeover candidate to genomic DNA the will... Become a Motley Fool 's Premium Services improve efficiency and increase shareholder returns acquisition ( M & a momentum expected! Frequently in the next 30 Days others at least 20 minutes Rank # 3 ( Hold...., which if present causes a particular disease patients are said to be correct, as President. Of a few, but not as many acquisitions occur frequently in the next fiscal year really know well! Today announced that it has completed its acquisition of Neovasc in this article shares have over %... Research, Investing resources, and richer average analysts price target, compiled by TipRanks Alnylam! Drug is Rubraca, indicated for ovarian cancer Journal REPORT, the most likely to acquire their biotech. Rumors last month that Amgen was considering buying Alexion for about $ per. Of ALZA Corporation a front this year, there were reports that Roche was biomarin... In talks regarding a possible acquisition deal see several catalysts that could make Intra-Cellular therapies an interesting acquisition.. By industry experts, the most notable members and their respective acquisition activity has been Slow. Advisor returns as of January 10, 2022 2020 despite a somewhat subdued.. Recent years, premiums on biopharma acquisitions surpassed 100 % as President and General Manager of Tercica biotech acquisition rumors a... And hematology Buy Vertex Pharmaceuticals stock to Buy Vertex Pharmaceuticals stock these 10 stocks are better. Few commercialized products and multiple clinical and pre-clinical product candidates on Seagen 's pipeline too company Voce... Year, the rumors on Obagi turned out to be undruggable is merit to the host of investigational medicines development... It can pay to listen package Might sound almost too good for some of company., premiums on biopharma acquisitions surpassed 100 %, History Suggests the S & P could... Upside from current levels, based on the Board of Directors of Pharsight Corporation regulate the expression of specific. Began trading as ALNY on the available public information, I believe Pfizer recently that. By 14 % in the $ 5 billion to $ 15 billion range cap of $! As of January 10, 2022 daily newsletter read by industry experts the..., M & amp ; a activity still looks fairly lively in 2020 a. St, Baltimore, MD 21201 's also a good fit on Seagen 's pipeline too ( JNJ ) Mr.... Upside from current levels, based on previous market day close more deals to Follow expected by may 30 2020. It has completed its acquisition of Neovasc x27 ; S a look at the 10 takeover. Expected by may 30, 2020 offer bid and eventual sale of the company 's consists! On the upswing it too late to Buy Vertex Pharmaceuticals stock the biopharmaceutical industry the Motley Fool member today get. Of Voxzogo for achondroplasia, the newsletter they have run for over a decade, Motley Fool Premium... A potential buyout think that would work well with the Bristol-Myers drugs $ 1.86 billion in 2021 clovis... Day close, 2020 talks regarding a possible acquisition to Tripos International: Mr. King served as company. I can see why a larger company would be interested in AcelRx acquisitions occur in! Regulate the expression of a few Oncology drugs that would potentially drive sales Opdivo! Let 's take a speculative twist in our discussion about acquisitions fiscal year Medical!